The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids
Copyright © 2022, Selvaraj et al..
Hyperinflammation is a key component of severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. It is imperative to distinguish severe COVID-19 from hyperinflammatory syndromes such as multisystem inflammatory syndrome (MIS) and hemophagocytic lymphohistiocytosis. There is a subset of post-COVID-19 patients who present with some symptoms characteristic of MIS in adults (MIS-A) yet do not meet all the criteria for a diagnosis. We describe the unique case of a patient with this kind of presentation who clinically improved following tocilizumab and corticosteroid usage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cureus - 14(2022), 2 vom: 21. Feb., Seite e22614 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Selvaraj, Vijairam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 05.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7759/cureus.22614 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339015543 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339015543 | ||
| 003 | DE-627 | ||
| 005 | 20231226001953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7759/cureus.22614 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1130.xml |
| 035 | |a (DE-627)NLM339015543 | ||
| 035 | |a (NLM)35371682 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Selvaraj, Vijairam |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022, Selvaraj et al. | ||
| 520 | |a Hyperinflammation is a key component of severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. It is imperative to distinguish severe COVID-19 from hyperinflammatory syndromes such as multisystem inflammatory syndrome (MIS) and hemophagocytic lymphohistiocytosis. There is a subset of post-COVID-19 patients who present with some symptoms characteristic of MIS in adults (MIS-A) yet do not meet all the criteria for a diagnosis. We describe the unique case of a patient with this kind of presentation who clinically improved following tocilizumab and corticosteroid usage | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a chis | |
| 650 | 4 | |a covid | |
| 650 | 4 | |a covid19 | |
| 650 | 4 | |a covid19 purgatory syndrome | |
| 650 | 4 | |a cps | |
| 650 | 4 | |a hyperinflammation | |
| 650 | 4 | |a hyperinflammatory syndrome | |
| 650 | 4 | |a mis-a | |
| 650 | 4 | |a sars-cov-2 | |
| 650 | 4 | |a sars-cov2 | |
| 700 | 1 | |a Finn, Arkadiy |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Dapaah-Afriyie, Kwame |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cureus |d 2013 |g 14(2022), 2 vom: 21. Feb., Seite e22614 |w (DE-627)NLM24118083X |x 2168-8184 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:2 |g day:21 |g month:02 |g pages:e22614 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7759/cureus.22614 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 2 |b 21 |c 02 |h e22614 | ||